October 6, 2025 Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference...
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients...
- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with...
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its continued...
BOSTON and SHANGHAI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics...
FDA-approved non-invasive treatment for depression and OCD now available at Contemporary Care’s Naples clinicImage by Contemporary Care NAPLES, Fla., Oct....
Geniant Cranial offers precision, compact footprint, and flexible patient positioning for hospitals seeking to enhance neurosurgical outcomes SAN DIEGO, Oct....
The Company expects to reestablish and announce a new record date as soon as possibleALAMEDA, Calif., Oct. 03, 2025 (GLOBE...
Small Business Innovation Research Grant will advance a novel neuroplastogen towards IND as potential treatment for Alcohol Use Disorder (AUD)....
Strategic integration fuels Asabys' goal to build a beyond €1 billion life sciences investment platform in Europe by 2030 Asabys incorporates...
This groundbreaking program harnesses neuroplasticity by combining the clinical strengths of counseling with the brain-enhancing power of exercise, offering a...
BOSTON, Oct. 1, 2025 /PRNewswire/ -- Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized...
Released in time for World Mental Health Day, "Transformed by His Promises" equips readers with clinically informed strategies and structured...
NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Today, a coalition of leaders from academia, healthcare, technology, and employee benefits announced the...
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting...
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company...
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead...
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...